Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
ChinaBio® Accelerator to Help Life Science Companies Establish China Operations
publication date: Jan 13, 2010
|
author/source: Richard Daverman, PhD
ChinaBio® LLC has formed a China domestic company, ChinaBio Accelerator (Shanghai) Company Ltd., to help US life science companies establish operations in China. With ChinaBio Accelerator’s help, companies will be able to enter the China market more quickly and with less risk than they could on their own.
The ChinaBio initiative mirrors a concept that has been used successfully in the web industry by Baidu, Google’s primary China competitor. ChinaBio believes its Accelerator is the first time the concept has been applied to the life science industry.
“The advantages of operating as a China domestic company are tremendous,” said Greg Scott, founder and CEO of ChinaBio LLC, and President for ChinaBio Accelerator. “We can help U.S. companies directly access government and private funding, technologies and markets that would normally not be available to them. They have a trusted partner that operates under U.S. law, ChinaBio LLC, but they also have access to China’s abundant resources directly through our China domestic company, ChinaBio Accelerator.”
Activity in the life sciences has increased significantly in China over the last three years. Most major pharma and many device and diagnostic companies have established R&D facilities there, validating China’s rise as a leading force in the industry.
Funding has also become widely available to China domestic companies through a variety of government sources. The central government’s Mega New Drug Development Program (MNDDP), which began funding companies late last year, is reported to be pumping over $12 billion USD into new drug development programs in China over the next five years. There are also numerous programs and funds available from provincial and municipal governments and agencies. For example, Suzhou, Guangzhou and Shenzhen each are said to have several billion dollar programs in place focused specifically on stimulating growth of the biotech and life science industry.
“Over our three year history in China, we have worked with most of the government agencies, life science parks and leading services companies here, and we can quickly identify financial, technical and support resources for our partners,” explained Ian Wisenberg, ChinaBio’s Senior Vice President of Strategic Development. “Depending on our partner’s needs, we can quickly have them operating under our structure in as little as two weeks. When appropriate, we can also establish a subsidiary company or JV for them that can provide direct access to China resources.”
Initially, the ChinaBio Accelerator will operate out of ChinaBio’s newly expanded Shanghai offices in Zhangjiang Hi-Tech Park. It expects to have facilities open in other life science parks later this year.
“We are the first and only company to determine how U.S. companies can take full advantage of the resources available to China domestic companies, and make it simple and safe for them to operate in China,” Scott concluded.
ChinaBio® LLC is based in San Diego and Shanghai. The company made the announcement of its new domestic China affiliate at the ChinaBio® Executive Workshop, which is being held during the JPMorgan Healthcare Conference in San Francisco.
About ChinaBio® LLC
Since its founding in January, 2007, ChinaBio LLC has rapidly launched a number of successful initiatives connecting the world with China biotech. With offices in Shanghai, Silicon Valley and San Diego, ChinaBio’s activities include:
• ChinaBio® Accelerator: Helping U.S. life science companies establish operations in China quickly, simple and safely, and access financial, scientific and support resources.
• Conferences: Organizer of the premier life science investment and partnering forums in China, ChinaBio has helped early stage China companies raise over USD 140 million to date.
• Consulting: Helping global life science companies, entrepreneurs and investors understand the China life science market, create a viable China strategy, and establish novel technologies and partners.
• Information: In-depth market intelligence and databases on novel technology development, clinical trials, and investment and partnering activity in China.
• ChinaBio® Today: Publishing online and email newsletters focusing exclusively on China’s life science industry.
More information is available at www.chinabiollc.com.
The ChinaBio initiative mirrors a concept that has been used successfully in the web industry by Baidu, Google’s primary China competitor. ChinaBio believes its Accelerator is the first time the concept has been applied to the life science industry.
“The advantages of operating as a China domestic company are tremendous,” said Greg Scott, founder and CEO of ChinaBio LLC, and President for ChinaBio Accelerator. “We can help U.S. companies directly access government and private funding, technologies and markets that would normally not be available to them. They have a trusted partner that operates under U.S. law, ChinaBio LLC, but they also have access to China’s abundant resources directly through our China domestic company, ChinaBio Accelerator.”
Activity in the life sciences has increased significantly in China over the last three years. Most major pharma and many device and diagnostic companies have established R&D facilities there, validating China’s rise as a leading force in the industry.
Funding has also become widely available to China domestic companies through a variety of government sources. The central government’s Mega New Drug Development Program (MNDDP), which began funding companies late last year, is reported to be pumping over $12 billion USD into new drug development programs in China over the next five years. There are also numerous programs and funds available from provincial and municipal governments and agencies. For example, Suzhou, Guangzhou and Shenzhen each are said to have several billion dollar programs in place focused specifically on stimulating growth of the biotech and life science industry.
“Over our three year history in China, we have worked with most of the government agencies, life science parks and leading services companies here, and we can quickly identify financial, technical and support resources for our partners,” explained Ian Wisenberg, ChinaBio’s Senior Vice President of Strategic Development. “Depending on our partner’s needs, we can quickly have them operating under our structure in as little as two weeks. When appropriate, we can also establish a subsidiary company or JV for them that can provide direct access to China resources.”
Initially, the ChinaBio Accelerator will operate out of ChinaBio’s newly expanded Shanghai offices in Zhangjiang Hi-Tech Park. It expects to have facilities open in other life science parks later this year.
“We are the first and only company to determine how U.S. companies can take full advantage of the resources available to China domestic companies, and make it simple and safe for them to operate in China,” Scott concluded.
ChinaBio® LLC is based in San Diego and Shanghai. The company made the announcement of its new domestic China affiliate at the ChinaBio® Executive Workshop, which is being held during the JPMorgan Healthcare Conference in San Francisco.
About ChinaBio® LLC
Since its founding in January, 2007, ChinaBio LLC has rapidly launched a number of successful initiatives connecting the world with China biotech. With offices in Shanghai, Silicon Valley and San Diego, ChinaBio’s activities include:
• ChinaBio® Accelerator: Helping U.S. life science companies establish operations in China quickly, simple and safely, and access financial, scientific and support resources.
• Conferences: Organizer of the premier life science investment and partnering forums in China, ChinaBio has helped early stage China companies raise over USD 140 million to date.
• Consulting: Helping global life science companies, entrepreneurs and investors understand the China life science market, create a viable China strategy, and establish novel technologies and partners.
• Information: In-depth market intelligence and databases on novel technology development, clinical trials, and investment and partnering activity in China.
• ChinaBio® Today: Publishing online and email newsletters focusing exclusively on China’s life science industry.
More information is available at www.chinabiollc.com.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China
